Quoin Pharma rises on FDA nod for skin disorder therapy study

Quoin Pharmaceuticals

25/04/2022 15:45

** U.S.-listed shares of Israel-based biotech co  QNRX.O 
rise ~14% to $1.2
    ** Co says U.S. FDA has granted clearance to begin clinical
testing of its experimental topical lotion, QRX003, for treating
Netherton Syndrome (NS), a rare congenital skin disorder
 urn:newsml:reuters.com:*:nGNXDmM6r
    ** Co expects to start trial in H1 of this year
    ** Currently, there is no cure or any approved therapeutic
treatments for NS - QNRX
    ** Stock down ~35% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))